Curated News
By: NewsRamp Editorial Staff
June 24, 2026

Helus Pharma Raises $50M to Advance Depression, Anxiety Programs

Discuss on Substack View History of this news story on GitHub
Original Source

TLDR

  • Helus Pharma raised $50M to advance depression and anxiety treatments, potentially outpacing competitors.
  • Helus Pharma priced 10.3M shares at $4.85, with proceeds funding Phase 3 depression and Phase 2 anxiety trials.
  • Helus Pharma's novel serotonergic agonists aim to improve mental health treatments for depression and anxiety.
  • Helus Pharma's HLP003 for major depressive disorder received FDA Breakthrough Therapy Designation, accelerating development.

Impact - Why it Matters

This news matters because Helus Pharma is targeting major depressive disorder and generalized anxiety disorder with novel therapies that could offer durable improvements for millions suffering from these conditions. The $50 million raise accelerates Phase 3 and Phase 2 trials, potentially bringing new treatment options to market faster. Investors and patients should watch for upcoming data readouts that could reshape the mental health landscape.

Summary

Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), the commercial operating name of Cybin Inc., has announced the pricing of an underwritten public offering of 10.3 million common shares at $4.85 per share, expecting gross proceeds of approximately $50 million. The offering, managed by joint bookrunning managers Cantor and Barclays, is set to close on June 25, 2026, subject to customary conditions. The company plans to use the net proceeds to advance its clinical pipeline, particularly the HLP003 program for major depressive disorder, with Phase 3 APPROACH topline data expected in Q4 2026. Additionally, funds will support HLP004 for generalized anxiety disorder and HLP005, along with working capital and general corporate purposes.

Helus Pharma, founded in 2019, is a clinical-stage pharmaceutical company focused on developing proprietary novel serotonergic agonists (NSAs) designed to activate serotonin pathways and promote neuroplasticity. These synthetic molecules aim to address unmet needs in mental health conditions such as depression and anxiety. The lead candidate, HLP003, has received Breakthrough Therapy Designation from the U.S. FDA and is in Phase 3 trials for adjunctive treatment of major depressive disorder. HLP004 is in Phase 2 for generalized anxiety disorder, and the company also has an extensive research portfolio of investigational NSAs.

This funding milestone highlights Helus Pharma's commitment to transforming mental health treatment through innovative science. The company operates in Canada, the US, the UK, and Ireland. For more details, the full press release is available at https://ibn.fm/yrchX. InvestorWire, a specialized communications platform, syndicated this news as part of its services within the Dynamic Brand Portfolio @ IBN.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Helus Pharma Raises $50M to Advance Depression, Anxiety Programs

blockchain registration record for this content.